Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 9/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.34 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15149262 | 0.76 | HSD11B1 (0.40) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL21593659 | 0.75 | CHRNB2 (0.47) | SMN1; SMN2CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL1237992 | 0.74 | HSD11B1 (0.43) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL3424501 | 0.73 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| Adamantane SCHEMBL28005909 | 0.73 | LMNA (0.50) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL24158929 | 0.70 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNA3CHRNB3 | |
| SCHEMBL2302714 | 0.70 | CHRNB2 (0.45) | SMN1; SMN2CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL18403419 | 0.70 | CHRM2 (0.55) | SMN1; SMN2CHRNB2CHRNA4CHRNA3HSD11B1 | |
| SCHEMBL23245840 | 0.70 | CHRM2 (0.55) | SMN1; SMN2CHRNB2CHRNA4CHRNA3HSD11B1 | |
| SCHEMBL17856437 | 0.70 | SMN1; SMN2 (0.42) | SMN1; SMN2CHRNB2CHRNA4CHRNA3CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423212-B1 | PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-06-01 | — | — | EP | disclosed |
| EP-2221306-B1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL IND LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-2221306-B1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL IND LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| CN-102405221-B | Process for production of 2-azaadamantane compound from bicyclocarbamate compound | NISSAN CHEMICAL IND LTD | 2015-01-21 | — | — | CN | disclosed |
| US-8669367-B2 | Method for producing 2-azaadamantane | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-8669367-B2 | Method for producing 2-azaadamantane | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-03-11 | — | — | US | disclosed |
| CN-101861315-B | Method for producing 2-azaadamantane | NISSAN CHEMICAL IND LTD | 2013-01-16 | — | — | CN | disclosed |
| US-8329909-B2 | Method for producing 2-azaadamantane compound from bicyclocarbamate compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120310005-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | TOHOKU TECHNO ARCH CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20120310005-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | TOHOKU TECHNO ARCH CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8273889-B2 | Method for producing 2-azaadamantane | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273889-B2 | Method for producing 2-azaadamantane | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| CN-102405221-A | Process for production of 2-azaadamantane compound from bicyclocarbamate compound | NISSAN CHEMICAL IND LTD | 2012-04-04 | — | — | CN | disclosed |
| US-20120053348-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2423212-A1 | PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| CN-101861315-A | The manufacture method of 2-aza-adamantane class | NISSAN CHEMICAL IND LTD | 2010-10-13 | — | — | CN | disclosed |
| EP-2221306-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | Nissan Chemical Industries, Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | CYP21A2, CYP51A1, CYP19A1 | SMN1; SMN2 3433/4885CHRNB2 2211/4885CHRNA4 2274/4885 |
| US-20120310005-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | CYP21A2, CYP51A1, CYP19A1 | SMN1; SMN2 3433/4885CHRNB2 2211/4885CHRNA4 2274/4885 |
| US-20120053348-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | CNKSR1, HDAC11, HDAC1 | SMN1; SMN2 4851/4885CHRNB2 2934/4885CHRNA4 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.